Nu-Med Plus, Inc. (NUMD)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NUMD steht fuer Nu-Med Plus, Inc., ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Bewertet mit 49/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 17. März 2026Nu-Med Plus, Inc. (NUMD) Gesundheitswesen & Pipeline-Uebersicht
Nu-Med Plus, Inc. is a medical device company specializing in nitric oxide delivery systems for hospitals, health systems, and research applications. With a focus on innovation and commercialization, the company operates in a competitive landscape of medical device manufacturers, facing challenges in market penetration and financial sustainability.
Investmentthese
Investing in Nu-Med Plus, Inc. presents a high-risk, high-reward scenario. The company's focus on nitric oxide delivery systems addresses a specific need within the medical community, potentially offering significant growth opportunities. However, with a market capitalization of $0.00B and a negative P/E ratio of -16.98, the company's financial stability is a major concern. The negative beta of -3.24 suggests an inverse correlation with the market, which could be attractive during economic downturns but also indicates unique company-specific risks. The company's future hinges on successful product commercialization and securing additional funding. Investors should carefully weigh the potential benefits against the substantial risks before considering an investment in NUMD.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap of $0.00B indicates a micro-cap company with limited resources and high volatility.
- P/E Ratio of -16.98 reflects negative earnings, suggesting the company is not currently profitable.
- Profit Margin of -9019.8% highlights significant operational inefficiencies and substantial losses.
- Gross Margin of 50.0% indicates potential profitability at the product level, but high operating expenses erode overall profitability.
- Beta of -3.24 suggests the stock is inversely correlated with the market, offering potential diversification benefits but also indicating company-specific risks.
Wettbewerber & Vergleichsunternehmen
Staerken
- Specialized expertise in nitric oxide delivery systems.
- Potential for innovative product development.
- Focus on a niche market segment.
- Proprietary technology.
Schwaechen
- Limited financial resources.
- Small team size (2 employees).
- Lack of established market presence.
- Dependence on successful product commercialization.
Katalysatoren
- Ongoing: Development of new nitric oxide delivery applications could expand market reach.
- Upcoming: Potential regulatory approvals for new products can drive revenue growth.
- Ongoing: Strategic partnerships with hospitals and health systems can provide access to established distribution channels.
Risiken
- Ongoing: Intense competition from established medical device manufacturers.
- Ongoing: Stringent regulatory requirements can delay or prevent product commercialization.
- Potential: Limited financial resources may hinder growth and development.
- Potential: Dependence on successful product commercialization increases the risk of failure.
- Ongoing: The company's small size and limited resources pose challenges to its long-term viability.
Wachstumschancen
- Expansion into Emerging Markets: Nu-Med Plus, Inc. can pursue growth by expanding its market reach into emerging economies where healthcare infrastructure is developing and demand for advanced medical devices is increasing. The global market for medical devices in emerging economies is projected to grow at a CAGR of 8-10% over the next five years, offering a significant opportunity for NUMD to increase its revenue and market share. Success hinges on navigating regulatory hurdles and establishing strategic partnerships in these regions.
- Strategic Partnerships with Hospitals and Health Systems: Collaborating with hospitals and health systems can provide Nu-Med Plus, Inc. with access to established distribution channels and a broader customer base. By partnering with key healthcare providers, NUMD can integrate its nitric oxide delivery systems into existing treatment protocols and gain valuable market validation. The timeline for establishing these partnerships is estimated at 1-2 years, with potential revenue impact within 2-3 years of implementation.
- Development of New Nitric Oxide Delivery Applications: Nu-Med Plus, Inc. can invest in research and development to expand the applications of its nitric oxide delivery systems beyond current uses. Exploring new therapeutic areas, such as pulmonary hypertension, wound healing, and cardiovascular diseases, can open up new market segments and drive revenue growth. The R&D timeline is estimated at 2-3 years, with potential commercialization within 3-5 years.
- Securing Regulatory Approvals for New Products: Obtaining regulatory approvals from agencies like the FDA is crucial for Nu-Med Plus, Inc. to commercialize its products and gain market access. Successfully navigating the regulatory process for new nitric oxide delivery systems can provide a significant competitive advantage and drive revenue growth. The regulatory approval process typically takes 1-3 years, depending on the complexity of the device and the clinical data required.
- Acquisition or Merger with a Larger Medical Device Company: Nu-Med Plus, Inc. could explore strategic opportunities such as an acquisition or merger with a larger medical device company to gain access to additional resources, expertise, and distribution channels. This could accelerate the company's growth and enhance its market position. The timeline for such a transaction is highly variable, but could potentially be completed within 1-2 years.
Chancen
- Expansion into emerging markets.
- Strategic partnerships with hospitals and health systems.
- Development of new nitric oxide delivery applications.
- Securing regulatory approvals for new products.
Risiken
- Intense competition from established medical device manufacturers.
- Stringent regulatory requirements.
- Risk of product obsolescence.
- Difficulty in securing funding.
Wettbewerbsvorteile
- Proprietary nitric oxide delivery technology.
- Specialized focus on a niche market.
- Potential for intellectual property protection through patents.
Ueber NUMD
Nu-Med Plus, Inc., incorporated in 2011 and headquartered in Salt Lake City, Utah, is a medical device company engaged in the design, development, enhancement, and commercialization of medical devices globally. The company focuses on nitric oxide delivery systems, offering a range of products including a hospital nitric oxide delivery system, a clinical nitric oxide delivery system, a mobile rechargeable device for nitric oxide gas delivery, and a nitric oxide system for research applications. These systems are designed to serve hospitals, health systems, and the broader medical community. Nu-Med Plus aims to improve patient care through innovative nitric oxide delivery solutions. However, as a small company with only two employees, it faces significant challenges in scaling its operations, securing funding, and competing with larger, more established players in the medical device industry. The company's success hinges on its ability to navigate regulatory hurdles, establish strategic partnerships, and effectively commercialize its products.
Was das Unternehmen tut
- Designs and develops medical devices.
- Specializes in nitric oxide delivery systems.
- Offers hospital nitric oxide delivery systems.
- Provides clinical nitric oxide delivery systems.
- Develops mobile rechargeable nitric oxide delivery devices.
- Creates nitric oxide systems for research applications.
Geschaeftsmodell
- Develops and sells nitric oxide delivery systems.
- Targets hospitals, health systems, and the medical community.
- Generates revenue through product sales.
Branchenkontext
Nu-Med Plus, Inc. operates within the medical device industry, a sector characterized by rapid innovation, stringent regulatory requirements, and intense competition. The global medical device market is projected to reach trillions of dollars by 2026, driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. Nu-Med Plus competes with established medical device manufacturers like BNVIF, CRYM, CSSI, KLYG, and MSIU, as well as smaller, specialized firms. The company's success depends on its ability to differentiate its nitric oxide delivery systems, navigate regulatory pathways, and secure market share in a crowded landscape.
Wichtige Kunden
- Hospitals
- Health systems
- Medical community
Finanzdaten
Chart & Info
Nu-Med Plus, Inc. (NUMD) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer NUMD verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer NUMD.
Kursziele
Wall-Street-Kurszielanalyse fuer NUMD.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von NUMD auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: William R. Colvin
CEO
William R. Colvin serves as the CEO of Nu-Med Plus, Inc. His background includes experience in managing small teams and guiding early-stage companies. While specific details on his prior roles and educational background are not available, his leadership is focused on driving the development and commercialization of Nu-Med Plus's nitric oxide delivery systems. He is responsible for the overall strategic direction and operational execution of the company.
Erfolgsbilanz: As CEO of Nu-Med Plus, Inc., William R. Colvin is responsible for overseeing the company's efforts to develop and commercialize its nitric oxide delivery systems. Given the company's small size and early stage, his track record is closely tied to the company's progress in securing funding, navigating regulatory hurdles, and establishing strategic partnerships. The success of Nu-Med Plus will depend on his ability to effectively manage resources and execute the company's business plan.
NUMD OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nu-Med Plus, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial reporting, increasing the risk for investors. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may have a higher risk of fraud or mismanagement.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases the risk of investing in NUMD.
- Low trading volume and wide bid-ask spreads can lead to significant price volatility.
- The OTC Other tier carries a higher risk of fraud or mismanagement.
- The company's small size and limited resources pose challenges to its long-term viability.
- Dependence on successful product commercialization increases the risk of failure.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's competitive landscape and market position.
- Evaluate the company's intellectual property and patent portfolio.
- Determine the company's cash flow and ability to fund its operations.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Company has been incorporated since 2011.
- Focus on developing innovative nitric oxide delivery systems.
- Serves hospitals, health systems, and the medical community.
- Has a CEO in place.
Haeufige Fragen zu NUMD
What are the key factors to evaluate for NUMD?
Nu-Med Plus, Inc. (NUMD) currently holds an AI score of 49/100, indicating low score. Key strength: Specialized expertise in nitric oxide delivery systems.. Primary risk to monitor: Ongoing: Intense competition from established medical device manufacturers.. This is not financial advice.
How frequently does NUMD data refresh on this page?
NUMD prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NUMD's recent stock price performance?
Recent price movement in Nu-Med Plus, Inc. (NUMD) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized expertise in nitric oxide delivery systems.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NUMD overvalued or undervalued right now?
Determining whether Nu-Med Plus, Inc. (NUMD) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NUMD?
Before investing in Nu-Med Plus, Inc. (NUMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding NUMD to a portfolio?
Potential reasons to consider Nu-Med Plus, Inc. (NUMD) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Specialized expertise in nitric oxide delivery systems.. Additionally: Potential for innovative product development.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of NUMD?
Yes, most major brokerages offer fractional shares of Nu-Med Plus, Inc. (NUMD) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track NUMD's earnings and financial reports?
Nu-Med Plus, Inc. (NUMD) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for NUMD earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on publicly available sources and may be limited.
- Financial data may not be up-to-date due to the company's OTC listing.